Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trial

International Journal of Obesity volume 25, pages 496–501 (2001)Cite this article

Abstract

BACKGROUND: In this report we assess pre-treatment determinants of weight loss and maintenance outcome in The Sibutramine Trial of Obesity Reduction and Maintenance (STORM), a 2 y randomized, double-blind, placebo-controlled, European multicenter study examining the effect of sibutramine (Sib) on inducing and maintaining weight loss in obese subjects.

MATERIAL: A total of 605 obese patients (BMI: 30–45 kg/m2) of both gender were included from eight European centers and treated for 24 months. The patients were treated for the initial 6 months by Sib (10 mg/day) and a low-fat low-energy, individualized diet (600 kcal/day deficit). The 467 patients who achieved >5% weight loss after 6 months were randomized 3:1 to Sib (10 mg/day) (Sib/Sib) and placebo (Sib/Pla) for weight maintenance over a further 18 months.

MAIN OUTCOME AND ANALYSES: Pre-treatment individual characteristics were assessed as predictors of 6 months weight loss (kg) and 24 months weight maintenance using simple and multivariate correlation and regression analyses.

RESULTS: In univariate analyses, the 6 month weight loss (n=505) was positively associated with pre-treatment body weight (r=0.27), height (r=0.18), fat-free mass (r=0.21) (all P<0.001), fat mass (r=0.13, P0.03), and resting metabolic rate (r=0.13, P<0.003). However, no relation was found with age, gender, smoking status, age at onset of obesity, or number of previous slimming attempts. The same predictors were found for weight change to endpoint in the Sib/Sib group (n=350), while no predictors were identified in the Sib/Pla (n=114). In the multivariate regression analysis only pre-treatment body weight predicted weight loss at 6 months (P<0.001). Weight change (kg) to 24 month was predicted by: 4.34+0.07*body weight (kg)−4*treatment (Sib=1, Pla=0)−0.06*age (y), (r2=8%, P<0.001).

CONCLUSION: Only pre-treatment body weight seems to be an important independent predictor of 6 months weight loss and 24 month weight maintenance in this study on diet and Sib. As only 8% of the variation in 24 months weight change could be explained by the predictors, the clinical value of this information is limited.

International Journal of Obesity (2001) 25, 496–501

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Astrup A, Buemann B, Gluud C, Bennett P, Tjur T, Christensen NJ . Prognostic markers for diet-induced weight loss in obese women Int J Obes Relat Metab Disord 1995 19: 275–278.

    CAS  PubMed  Google Scholar 

  2. Bild DE, Sholinsky P, Smith DE, Lewis CE, Hardin JM, Burke GI . Correlates and predictors of weight loss in young adults: the CARDIA study. Int J Obes Relat Metab Disord 1996 20: 47–55.

    CAS  PubMed  Google Scholar 

  3. Bray GA, Ryan DH, Gordon D, Heidingsfelder S, Cerise F, Wilson K . A double-blind randomized placebo-controlled trial of sibutramine. Obes Res Relat Metab Disord 1996 4: 263–270.

    CAS  Google Scholar 

  4. Froidevaux F, Schutz Y, Christin L, Jequier E . Energy expenditure in obese vomen before and during weight loss, after refeeding, and in weight-relapse period Am J Clin Nutr 1993 57: 35–42.

    Article  CAS  Google Scholar 

  5. Grundlah C, Heal DJ, Auerbach SB . In vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents: sibutramine is a reuptake inhibitor J Pharmac Exp Ther 1997 283: 581–591.

    Google Scholar 

  6. Hanotin C, Thomas F, Jones SP, Leutenegger E, Drouin P . Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study Int J Obes Relat Metab Disord 1998 22: 32–38.

    Article  CAS  Google Scholar 

  7. Hansen DL, Toubro S, Stock MJ, Macdonald IA, Astrup A . The effect of sibutramine on energy expenditure and appetite during chronic treatment without any dietary restriction Int J Obes Relat Metab Disord 1999 23: 1016–1024.

    Article  CAS  Google Scholar 

  8. Hansen DL, Toubro S, Stock MJ, Macdonald IA, Astrup AV . Thermogenic effects of sibutramine in humans Am J Clin Nutr 1998 68: 1180–1186.

    Article  CAS  Google Scholar 

  9. James WPT, Astrup A, Finer N, Hilsted J, Kopelman P, Rössner S, Saris WHM, Van Gaal LF . A two year sibutramine trial of obesity reduction and maintenance Lancet (submitted).

  10. Pasman WJ, Saris WHM, Westerterp-Plantenga MS . Predictors of weight maintenance Obes Res 1999 7: 43–50.

    Article  CAS  Google Scholar 

  11. Rössner S . Defining success in obesity management Int J Obes Relat Metab Disord 1997 21 (Suppl 1): S2–4.

    PubMed  Google Scholar 

  12. Seagle HM, Bessesen DH, Hill JO . Effects of sibutramine on resting metabolic rate and weight loss in overweight women Obes Res 1998 6: 115–121.

    Article  CAS  Google Scholar 

  13. Toornvliet AC, Pijl H, Hopman E, Westendorp RGJ, Meinders AE . Predictors of weight loss during treatment with d-fenfluramine J Intern Med 1997 241: 401–406.

    Article  CAS  Google Scholar 

  14. Torgerson JS, Carlson B, Stenlöf K, Carlson L, Bringman E, Sjöström L . A low serum leptin level at baseline and a large early decline in leptin predicts a large 1-year weight reduction in energy-restricted obese humans J Clin Endocrinol Metab 1999 84: 4197–4203.

    CAS  PubMed  Google Scholar 

  15. Wadden TA, Bartlett S, Letizia KL, Foster GD, Stunkard AJ, Conill AM . Relationship of dieting history to resting metabolic rate, body composition, eating behavior and subsequent weight loss Am J Clin Nutr 1992 56 (Suppl 1): 203S–208S.

    Article  CAS  Google Scholar 

  16. Wadden TA, Foster GD, Wang J, Pierson RN, Yang MU, Moreland K, Stunkard AJ, VanItallie T . Clinical correlates of short and long-term weight loss Am J Clin Nutr 1992 56 (Suppl 1): 271S–274S.

    Article  CAS  Google Scholar 

  17. Webster JD, Garrow J . Weight loss in 108 obese women on a diet supplying 800 kcal/d for 21 d Am J Clin Nutr 1989 50: 41–45.

    Article  CAS  Google Scholar 

  18. Weintraub M, Byrne L, Golik A, Rubio A . Sibutramine in weght control: a dose-ranging, efficacy study Clin Pharmac Ther 1991 50: 330–337.

    Article  CAS  Google Scholar 

  19. Weintraub M, Taves DR, Hasday JD, Mushlin AI, Lockwood DH . Determinants of response to anorexiants Clin Pharmac Ther 1981 30: 528–533.

    Article  CAS  Google Scholar 

Download references

Author information

Author notes

  1. M Goulder: The STORM teams in each center provided excellent support throughout the study. The individuals involved were: Rowett Research Institute, Aberdeen (Dr T Gill, Ms M van Wijk, Dr L Patience, Dr L Berrow, Ms J Whitehead, Ms C Garnham, Ms F Cordiner, Ms L Nellis, Ms L Penny); University Hospital, Antwerp (Professor I De Leeuw, Dr N Gubbels, Ms I Mertens, Dr F Peiffer, Ms A Van de Sompel, Ms M Wauters); The Royal Veterinary and Agricultural University, Copenhagen (Ms A Vedelspang, Ms U Pedersen); Hvidovre Hospital, Copenhagen (Dr P Porsborg, Ms G Stage Hansen, Ms L Kristoffersen); Luton and Dunstable Hospital, Luton (Ms C Coomber, Ms S Feben, Ms K Jarret, Dr N Lessan Dr I Packianathan, Dr A Stork, Ms M Sheikh, Ms L Young, Ms N Orr); The Royal London Hospital, London (Dr L Albon, Dr A Qureshi, Ms C Grace, Ms D Whicheloe, Ms B Maclaughlin); University of Limburg, Maastricht (Dr E van Mil, Professor M van Baak, Ms T Hermans-Limpens, Ms J Suiten); and Karolinska Hospital, Stockholm (Dr M Holst, Dr M Lördal, Dr A Fernström, Dr O Soder, Ms A Hägg, Ms C Johannson, Ms B Hannikäinen, Ms L Flinth, Ms E Fredriksson, Ms T Persson, Ms C Grimming). The STORM study was sponsored by a grant from BASF Pharma.

Authors and Affiliations

  1. Research Department of Human Nutrition and Centre for Advanced Food Science (LMC), The Royal Veterinary and Agricultural University, Frederiksberg, Denmark

    DL Hansen, A Astrup & S Toubro

  2. Luton and Dunstable Hospital, Luton, UK

    N Finer

  3. The Royal London Hospital, London, UK

    P Kopelman

  4. Hvidovre Hospital, Copenhagen, Denmark

    J Hilsted

  5. Karolinska Hospital, Stockholm, Sweden

    S Rössner

  6. University of Limburg, Maastricht, The Netherlands

    WHM Saris

  7. University Hospital Antwerp, Antwerp, Belgium

    LF Van Gaal

  8. The Rowett Research Institute, Aberdeen, UK

    WPT James

  9. BASF Pharma, Nottingham, UK

    M Goulder

Authors
  1. DL Hansen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Astrup
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Toubro
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N Finer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P Kopelman
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J Hilsted
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S Rössner
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. WHM Saris
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. LF Van Gaal
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. WPT James
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. M Goulder
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

for the STORM study group

Corresponding author

Correspondence to A Astrup.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hansen, D., Astrup, A., Toubro, S. et al. Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trial. Int J Obes 25, 496–501 (2001). https://doi.org/10.1038/sj.ijo.0801481

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijo.0801481

Keywords

This article is cited by

Search

Advanced search

Quick links